Edition:
United States

Acceleron Pharma Inc (XLRN.OQ)

XLRN.OQ on NASDAQ Stock Exchange Global Market

44.50USD
23 Jan 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$44.50
Open
$44.63
Day's High
$45.00
Day's Low
$43.79
Volume
166,899
Avg. Vol
145,475
52-wk High
$46.51
52-wk Low
$23.07

Chart for

About

Acceleron Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta... (more)

Overall

Beta: 1.52
Market Cap(Mil.): $1,959.86
Shares Outstanding(Mil.): 44.04
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 216.73 18.18
EPS (TTM): -- -- --
ROI: -- -7.31 33.32
ROE: -- -28.55 17.09

BRIEF-Acceleron plans to initiate part 2 of ACE-083 FSHD phase 2 trial during Q2 of 2018

* ACCELERON PHARMA INC - PLANS TO INITIATE PART 2 OF ACE-083 FSHD PHASE 2 TRIAL DURING Q2 OF 2018

Jan 08 2018

BRIEF-BioAg Alliance Announces Updated Research And Development Pipeline

* BIOAG ALLIANCE - ANNOUNCED UPDATED RESEARCH AND DEVELOPMENT PIPELINE

Jan 04 2018

BRIEF-Acceleron ‍expects to initiate a phase 2 trial in 1H 2018​

* Acceleron announces preclinical results in pulmonary arterial hypertension at the American Heart Association 2017 Scientific Sessions

Nov 14 2017

BRIEF-Acceleron Pharma qtrly net loss per share $0.65

* Acceleron Pharma reports third quarter 2017 operational and financial results

Nov 07 2017

BRIEF-Acceleron announces pricing of public offering of common stock

* Acceleron announces pricing of public offering of common stock

Sep 20 2017

BRIEF-Acceleron announces proposed public offering of common stock

* Acceleron announces proposed public offering of common stock

Sep 19 2017

BRIEF-Acceleron Pharma Q2 loss per share $0.77

* Acceleron Pharma reports second quarter 2017 operational and financial results

Aug 03 2017

BRIEF-Acceleron announces first patient treated in phase 2 clinical trial of ACE-083

* Acceleron announces first patient treated in phase 2 clinical trial of ACE-083 in Charcot-Marie-Tooth disease Source text for Eikon: Further company coverage:

Aug 01 2017

Earnings vs. Estimates